• 1
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin. 1997; 48: 629.
  • 2
    Gittes RF. Carcinoma of the prostate. N Eng J Med. 1990; 324: 236.
  • 3
    Huggins C, Hodges CV. Studies on prostate cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 2937.
  • 4
    The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Eng J Med. 1984; 311: 12811286.
  • 5
    Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973; 32: 11261130.
  • 6
    Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol. 1985; 3: 827841.
  • 7
    Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol. 1992; 11: 17541761.
  • 8
    Seidman A, Scher H, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol. 1992; 147: 931934.
  • 9
    Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999; 17: 31603166.
  • 10
    Jordan MA, Margolis RL, Himes RH. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol. 1986; 187: 61.
  • 11
    Benson R, Hartley-Asp B. Mechanism of action and clinical uses of estramustine. Cancer Invest. 1990; 8: 375380.
  • 12
    Tew K, Sterns M. Hormone independent non-alkylating mechanism of cytotoxicity for estramustine. Urol Res. 1987; 15: 155160.
  • 13
    Blake GM, Zivanovic M, McEwan J, et al. Sr-89: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986; 12: 447454.
  • 14
    Blake GM, Zivanovic M, Blaquiere R, et al. Strontium-89 therapy: measurement of absorbed dose to skeletal malignancy. J Nucl Med. 1988; 29: 549557.
  • 15
    Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991; 27: 954958.
  • 16
    Coriens HJ, Mebel M, Buchalik, et al. Strontium-89 therapy for bone metastases of carcinoma of the prostate gland. Eur J Nucl Med. 1979; 4: 3335.
  • 17
    Firusian N, Mellin P, Schmidt CG, et al. Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from metastases: a preliminary report. J Urol. 1976; 116: 764798.
  • 18
    Siberstein EN, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985; 26: 345348.
  • 19
    Tenvall J, Darte L, Lundgren R, et al. Palliation of multiple bone metastases from prostate carcinoma with strontium-89. Acta Oncol. 1988; 27: 365369.
  • 20
    Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostate skeletal malignancy. Br J Radiol. 1991; 64: 816822.
  • 21
    Yoshida D, Piepmeier J, Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Can Res. 1994; 54: 14151417.
  • 22
    Kim JH, Khil M, Sang HK, et al. Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Rad Oncol Biol Phys. 1994; 29: 555557.
  • 23
    Khil MS, Kim JH, Bricker LJ, et al. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci. Am 1997; 3: 289296.
  • 24
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649652.
  • 25
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Accoc. 1958; 53: 457481.
  • 26
    Amato RJ, Logothetis CJ, Dexeus FH, et al. Preliminary results of a phase II trial of estramustine and vinblastine for patients with progressive hormone refractory prostate carcinoma [abstract]. Proc Am Assoc Cancer Res. 1991; 32: 186.
  • 27
    Attivissimo LA, Fetten JV, Kreis W. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol. 1996; 19: 581583.
  • 28
    Porter AT, McEwan AJB. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993; 20: 3843.
  • 29
    Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med. 1992; 33: 14371443.
  • 30
    Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001; 357: 336341.
  • 31
    Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B J Clin Oncol. 2001; 19: 25092516.